“5 of 10 TNF-αis prescribed last year were adalimumab”
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.02.13 10:15:59
가나다라
0
Evidnet analyzes prescription data from 10 general hospitals in Korea last year.
The most prescribed indication was adalimumab, followed by infliximab, etanercept, then golimumab
Indication for ankylosing spondylitis, rheumatoid arthritis, then Crohn's disease
On the 13th, the healthcare big data analysis service Evidnet released the results of its analysis on the prescription data of 10 general hospitals nationwide last year. According to the results, ‘adalimumab (Humira)’ was the most frequently prescribed TNF- α inhibitor last year.
Evidnet analyzed and announced 18,371 prescription data on TNF-α inhibitors from 10 general hospitals nationwide by indication and component last year.
According to Evidnet, the most prescribed TNF-α inhibitor was adalimumab, which accounted for 50.7% of all prescriptions last year. Next was infliximab (Remicade) at 20.2%, followed by etanercept (Enbrel) at 15.1%, then golimumab (Simponi) at 14.0%.
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)